Central Nervous System Lymphoma Initial Diagnosed as Tumefective Multiple Sclerosis after Brian Biopsy
Intern Med 52:483-488, Ohe, Y.,et al, 2013
Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Balos Concentric Lesions
Intern Med 52:1517-1521, Masuda, H.,et al, 2013
Cerebral Venous Thrombosis after High Dose Steroid in Multiple Sclerosis: A Case Report
Hippokratia 17:88-90, Gazioglu, S.,et al, 2013
Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Ann Neurol 74:679-687, Krueger, D.A.,et al, 2013
Clinical Features of MS Associated with Leber Hereditary Optic Neuropathy mtDNA Mutations
Neurol 81:2073-2081, Pfeffer, G.,et al, 2013
Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Subacute Sclerosing Panencephalitis
www.MedLink.com, February, Auwaeter,P.G.&Johnson,R.T., 2013
Spinal Cord Lesions in Patients with Clinically Isolated Syndrome
Neurol 80:69-75, Sombekke, M.,et al, 2013
The Thalamus and Multiple Sclerosis
Neurol 80:210-219, Minagar, A.,et al, 2013
Functional Impairment in Progressive Supranuclear Palsy
Neurol 80:380-384, Duff, K.,et al, 2013
Location of Brain Lesions Predicts Conversion of Clinically Isolated Syndromes to Multiple Sclerosis
Neurol 80:234-241, Giorgio, A.,et al, 2013
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013
Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200,2176, Maringer, R.,et al, 2013
Aquaporin-4 Antibody-Positive Cases Beyond Current Diagnosis Criteria for NMO Spectrum Disorders
Neurol 80:2210-2216, Sato, D.,et al, 2013
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Clinicopathologic Conference, Blind and Confused, Neuromyelitis Optica Spectrum Disorder
JAMA Neurol 70:932-936, Sharma, V.,et al, 2013
Extensive Vasogenic Edema of Anti-Aquaporin-4 Antibody-Related Brain Lesions
Mult Scler 15:1113-1117, Matsushita, T.,et al, 2013
Brain Abnormalities as an Initial Manifestation of Neuromyelitis Optica Spectrum Disorder
MSJ 17:1107-1112, Kim, W.,et al, 2013
Clinical Spectrum of CNS Aquaporin-4 Autoimmunity
Neurol 78:1179-1185, Kim, S.,et al, 2013
Differential Diagnosis of Neuromyelitis Optica Spectrum Disorders
Brain Neurol 62:953-960, Tanaka, T., 2013
Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200, 2176, Marignier, R.,et al, 2013
Characterising Aggressive Multiple Sclerosis
JNNP doi:10.1136 1-7, Menon, S.,et al, 2013
Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013
Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012
Brain Atrophy is Related to Lacunar Lesions and Tissue Microstructural Changes in CADASIL
Stroke 38:1786-1790, Jouvent, E.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Should we be nervous about coeliac disease? Brain abnormalities in patients with coeliac disease referred for neurologic opinion
JNNP 83:1216-1221, Currie, S.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012
Monosymptomatic Clinically Isolated Syndrome with Sudden Sensorineural Hearing Loss
The Neurologist 18:302-305, Anagnostouli, M.C.,et al, 2012
Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder
Multiple Sclerosis International ID 735486, Kim, W.,et al, 2012
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Recovery after Spinal Cord Infarcts
Neurol 78:114-121, Robertson,C.E.,et al, 2012
Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis verus Healthy Controls
AJNR 33:252258, Habib,C.A.,et al, 2012
Fingolimod-Associated Macular Edema
Neurol 78:672-680, Jain,N. and Bhatti,M.T., 2012
Serologic Diagnosis of NMO
Neurol 78:665-671, Waters,P.J.,et al, 2012
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012